SAN DIEGO, May 13, 2015 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, age-related macular degeneration and fibrotic diseases, today announced presentations for both TRC105 and TRC102 at the upcoming American Society of Clinical Oncology (ASCO) annual meeting to be held May 29-June 2, 2015, in Chicago, Illinois.
The following is a summary of the four presentations that will be given at ASCO:
|Poster Discussion Presentation|
|Title:||A Phase 1b dose-escalation study of TRC105 (anti-endoglin antibody) in combination with|
|pazopanib in patients with advanced soft tissue sarcoma (Abstract #10514)|
|Presenter:||Steven Attia, DO, Mayo Clinic-Jacksonville|
|Location:||S Hall A, Poster Board 158 (poster display)|
|S404 (poster discussion)|
|Date/Time:||Sunday, May 31, 2015, 8:00 AM – 11:30 AM, Central time (poster display)|
|Sunday, May 31, 2015, 4:30 PM – 5:45 PM, Central time (poster discussion)|
|General Poster Presentations|
|Title:||Phase 1 clinical trial of temozolomide and methoxyamine (TRC102) in patients with|
|advanced solid tumors (Abstract #2558)|
|Presenter:||Jennifer Rachel Eads, MD, Case Comprehensive Cancer Center, Case Western Reserve University|
|Location:||S Hall A, Poster Board 274|
|Date/Time:||Saturday, May 30, 2015, 8:00 AM – 11:30 AM, Central time|
|Title:||A Phase 1/2 study of TRC105 in combination with sorafenib in hepatocellular|
|carcinoma (Abstract #4083)|
|Presenter:||Austin G. Duffy, MD, National Cancer Institute|
|Location:||S Hall A, Poster Board 193|
|Date/Time:||Monday, June 1, 2015, 8:00 AM – 11:30 AM, Central time|
|Title:||Bevacizumab alone or in combination with TRC105 for metastatic renal cell cancer|
|(mRCC): A California Cancer Consortium clinical trial (Abstract #4542)|
|Presenter:||Tanya Dorff, MD, University of Southern California Norris Comprehensive Cancer Center|
|Location:||S Hall A, Poster Board 215|
|Date/Time:||Monday, June 1, 2015, 1:15 PM – 4:45 PM, Central time|
TRC105 is a novel, clinical stage antibody to endoglin, a protein overexpressed on proliferating endothelial cells that is essential for angiogenesis, the process of new blood vessel formation. TRC105 is currently being studied in clinical trials sponsored by both TRACON and the National Cancer Institute for the treatment of multiple solid tumor types in combination with VEGF inhibitors. TRC105 is also being developed in combination with VEGF inhibitor treatments in age-related macular degeneration. For more information about the clinical trials, please visit TRACON's website at http://www.traconpharma.com/clinical_trials.php.
TRC102 is a novel, clinical stage small molecule inhibitor of the DNA base excision repair pathway that causes resistance to alkylating and antimetabolite chemotherapeutics. TRC102 is currently being studied in clinical trials sponsored by both the National Cancer Institute and Case Comprehensive Cancer Center. For more information about the clinical trials, please visit TRACON's website at http://www.traconpharma.com/clinical_trials.php.
TRACON develops targeted therapies for cancer, age-related macular degeneration and fibrotic diseases. TRACON's current pipeline includes two clinical stage product candidates: TRC105, an anti-endoglin antibody that is being developed for the treatment of renal cell carcinoma, soft tissue sarcoma, hepatocellular carcinoma, glioblastoma and choriocarcinoma, and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.
CONTACT: Casey Logan Chief Business Officer (858) 550-0780 ext. 236 email@example.com
Source:TRACON Pharmaceuticals, Inc.